Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adipose tissue-derived mesenchymal stromal cells (AT-MSCs), also commonly referred to as adipose-derived stem cells (ASCs) or adipose-derived mesenchymal stem cells (ADMSCs), are multipotent stromal cells isolated from human adipose tissue, typically collected as lipoaspirate from procedures like liposuction[1][3][4]. These cells can differentiate into various mesenchymal lineages such as adipocytes, chondrocytes, and osteoblasts, and possess immunomodulatory and tissue-regenerative properties, both through direct differentiation and via secretion of paracrine factors[3][4][5]. AT-MSCs display a characteristic phenotype, being positive for markers CD73, CD90, and CD105, while lacking hematopoietic and endothelial markers such as CD34 and CD45[3][4]. Their accessibility, high yield, and proliferative capacity have made AT-MSCs an attractive tool for regenerative medicine and cell therapy, with ongoing clinical research in diverse indications including wound healing, cardiovascular disease, autoimmune disorders, and type 1 diabetes[4][5]. However, as a cell type and not a single molecular target (e.g., receptor, enzyme), they do not fit the definition of a classical therapeutic target, hence are not typically the direct target of small molecules or biologic drugs, but rather are used as therapeutic agents themselves in cell-based therapy[2][3][4]. Note: - This entry is marked is_incorrect: true because "Mesenchymal stromal/stem cells from adipose tissue" is a cell population, not a discrete molecular target such as a receptor, enzyme, or protein. This makes it unsuitable as a conventional molecular therapeutic target according to pharmacological or target-based drug discovery frameworks. - Additional entries such as "interacting_drugs" and "mechanism_of_action" are not applicable: drugs generally do not target these cells per se; instead, the cells are administered as cell therapies, or their secreted factors are studied for effects. - They are highly heterogeneous and encompass several subtypes and preparation protocols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adipose tissue-derived mesenchymal stromal cell (AT-MSC).